When was Second Sight founded?

Second Sight was founded in 2000 and raised its 1st funding round within a year of its incorporation.

Where is Second Sight located?

Second Sight is headquartered in Los Angeles, United States.

Who is the current CEO of Second Sight?

Adam Mendelsohn of Second Sight. They have also founded 2 companies.

How many employees does Second Sight have?

As of Mar 01, 2026, the latest employee count at Second Sight is 50 - 199.

Is Second Sight a funded company?

Second Sight is a funded company, having raised a total of $36.9M across 18 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2000.

When was the latest funding round of Second Sight?

Second Sight's latest funding was a $***** Grant (prize money) round on Jul 18, 2022, with participation from 1 investor.

What is the annual revenue of Second Sight?

Annual revenue of Second Sight is between $1M and $10M as on Dec 31, 2019

Where does Second Sight rank among its competitors?

Second Sight ranks 4th amongst 47 active competitors, of which 13 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Maculaser, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Second Sight?

Second Sight's top competitors include Neurotech, Eyedaptic and Cerevast. Among them, Maculaser secured the most recent funding round in May, 2026.

Second Sight - 2026 Company Profile, Team, Funding, Competitors & Financials

Second Sight is a public company based in Los Angeles (United States), founded in 2000 by Adam Mendelsohn. It operates as a Provider of an implantable visual prosthetic for blind individuals. Second Sight has raised $36.9M in funding. The company has 47 active competitors, including 13 funded and 7 that have exited. Its top competitors include companies like Neurotech, Eyedaptic and Cerevast.

Company Details

Provider of implantable visual prosthetics for blind individuals. The flagship product, Argus II Retinal Prosthesis System is an FDA and CE-approved device targeted for patients with severe to profound retinitis pigmentosa. Includes a miniature video camera housed in the patient's glasses, a patient-worn computer where data is processed and transformed into instructions transmitted wirelessly to an antenna in the retinal implant. The implant emits electrical pulses which create perceptions of patterns of light. Patients learn to interpret these visual patterns with their retinal implant. It is also developing the Visual Cortical Prosthesis, Orion for blinds due to preventable or treatable conditions.

Website: secondsight.com
Email ID: *****@secondsight.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2000

Location

Los Angeles, United States

Stage

Public

Total Funding

$36.9M in 18 rounds

Latest Funding Round

Grant (prize money), Jul 18, 2022, $*****

Investors

Versant Ventures & 3 more

Ranked

4^th among 47 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2019

Employee Count

50 - 199 as on Mar 01, 2026

Investment & Acquisitions

Tally Health & 2 more

Similar Companies

Neurotech & 53 more

Exit Details

Public

View Second Sight's full profile

Second Sight is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SECOND SIGHT MEDICAL PRODUCTS INC CIN: 1266806 , United States, Active		$5M - $25M (As on Dec 20, 2018)	-	-
VIVANI MEDICAL, INC. CIN: 1266806 , United States, Active	Jul 05, 2023	$1M - $10M (As on Dec 31, 2019)	37 (As on Dec 31, 2023)	-
Second Sight Medical Products, Inc. CIN: 02-0692322 , United States, Active	Dec 31, 1997	-	14 (As on Dec 31, 2022)	-

Second Sight got listed on Nov 19, 2014.

Click here to take a look at Second Sight's IPO in detail

Second Sight has raised a total funding of $36.9M over 18 rounds. Its first funding round was on Jul 01, 2000. Its latest funding round was a Grant (prize money) round on Jul 18, 2022 for $*****. 1 investor participated in its latest round. Second Sight has 4 institutional investors.

Here is the list of recent funding rounds of Second Sight:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 18, 2022	5118122	Grant (prize money)	3378544	5856273	2193180	1964012
May 18, 2021	2683837	Grant (prize money)	9182933	9285140	4333151	NIH
Mar 24, 2021	4515364	Post IPO	1815790	1699863	2637408	7130139

Access funding benchmarks and valuations. Sign up today!

View details of Second Sight's funding rounds and investors

The founders of Second Sight is Adam Mendelsohn. Adam Mendelsohn is the CEO of Second Sight.

Here are the details of Second Sight's key team members:

Adam Mendelsohn: Co-Founder & CEO of Second Sight and founder of 1 other company.

View details of Second Sight's Founder profiles and Board Members

Second Sight's employee count trend

Second Sight has 50 - 199 employees as of Mar 26. Here is Second Sight's employee count trend over the years:

Uncover Second Sight's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Second Sight include Neurotech, Eyedaptic and Cerevast. Here is the list of Top 10 competitors of Second Sight, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Neurotech 2000, Cumberland (United States), Series B	Developer of a cell-based delivery device for the treatment of eye diseases	$53.3M	Atlas Venture, 3i Group & 12 others	57/100
2nd	Eyedaptic 2016, Laguna Niguel (United States), Seed	Smart glasses enhancing vision for macular degeneration and low vision	$1.47M	Crescite Ventures, New York Angels & 2 others	52/100
3rd	Cerevast 2009, Bothell (United States), Series C	Medical device company developing innovative ultrasound and microsphere therapies	$46.9M	Swiftsure, Haiyin Capital	50/100
4th	Second Sight 2000, Los Angeles (United States), Public	Provider of an implantable visual prosthetic for blind individuals	$36.9M	Versant Ventures, MDB Capital & 2 others	49/100
5th	Maculaser 2018, Espoo (Finland), Seed	Developer of laser therapy for the treatment of retinal diseases	$1.45M	Innovestor, ZEISS & 3 others	48/100
6th	RecensMedical 2016, Ulsan (South Korea), Public	Developer of an anesthetic medical device for retinal diseases	-	Intops Investment, SOORIM venture capital ... & 3 others	48/100
7th	Pixium Vision 2011, Paris (France), Public	Provider of bionic vision restoration systems	$32.5M	Sofinnova Partners, Lifeblood Capital & 11 others	46/100
8th	iScience Interventional 1999, Menlo Park (United States), Acquired	Innovative medical device company focused on interventional solutions	$36.7M	Medtronic, Affinity Capital Management & 11 others	44/100
9th	Pykus Therapeutics 2016, Boston (United States), Seed	Develops a dissolvable intraocular device for use during retinal surgery	$2.49M	Mass General Brigham Ventures, Hongsen Investment ... & 5 others	37/100
10th	Medical Instrument Development Laboratories 1981, San Leandro (United States), Acquired	Innovating ophthalmic surgical devices to prevent blindness and improve global vision	$50M	SBCVC, Orbimed & 3 others	37/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Second Sight's competitors? Click here to see the top ones

Second Sight has made 2 investments in Tally Health and Pixium Vision and acquired Nano Precision Medical.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 06, 2023	Investments	Tally Health	2021	New York City (United States)
Feb 07, 2022	Acquisition	Nano Precision Medical	2009	Emeryville (United States)
Jan 05, 2021	Investments	Pixium Vision	2011	Paris (France)